JP2017514850A5 - - Google Patents

Download PDF

Info

Publication number
JP2017514850A5
JP2017514850A5 JP2016566238A JP2016566238A JP2017514850A5 JP 2017514850 A5 JP2017514850 A5 JP 2017514850A5 JP 2016566238 A JP2016566238 A JP 2016566238A JP 2016566238 A JP2016566238 A JP 2016566238A JP 2017514850 A5 JP2017514850 A5 JP 2017514850A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
htbz
isoquinolin
hours
pyrido
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016566238A
Other languages
English (en)
Japanese (ja)
Other versions
JP6635945B2 (ja
JP2017514850A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/029519 external-priority patent/WO2015171802A1/en
Publication of JP2017514850A publication Critical patent/JP2017514850A/ja
Publication of JP2017514850A5 publication Critical patent/JP2017514850A5/ja
Application granted granted Critical
Publication of JP6635945B2 publication Critical patent/JP6635945B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016566238A 2014-05-06 2015-05-06 多動性運動障害を処置するためのｖｍａｔ２インヒビター Active JP6635945B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461989240P 2014-05-06 2014-05-06
US61/989,240 2014-05-06
PCT/US2015/029519 WO2015171802A1 (en) 2014-05-06 2015-05-06 Vmat2 inhibitors for the treatment of hyperkinetic movement disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019181949A Division JP2019218407A (ja) 2014-05-06 2019-10-02 多動性運動障害を処置するためのｖｍａｔ２インヒビター

Publications (3)

Publication Number Publication Date
JP2017514850A JP2017514850A (ja) 2017-06-08
JP2017514850A5 true JP2017514850A5 (OSRAM) 2018-06-14
JP6635945B2 JP6635945B2 (ja) 2020-01-29

Family

ID=53264772

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2016566238A Active JP6635945B2 (ja) 2014-05-06 2015-05-06 多動性運動障害を処置するためのｖｍａｔ２インヒビター
JP2019181949A Withdrawn JP2019218407A (ja) 2014-05-06 2019-10-02 多動性運動障害を処置するためのｖｍａｔ２インヒビター
JP2021153918A Withdrawn JP2021191799A (ja) 2014-05-06 2021-09-22 多動性運動障害を処置するためのｖｍａｔ２インヒビター
JP2024122223A Pending JP2024153782A (ja) 2014-05-06 2024-07-29 多動性運動障害を処置するためのｖｍａｔ２インヒビター

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2019181949A Withdrawn JP2019218407A (ja) 2014-05-06 2019-10-02 多動性運動障害を処置するためのｖｍａｔ２インヒビター
JP2021153918A Withdrawn JP2021191799A (ja) 2014-05-06 2021-09-22 多動性運動障害を処置するためのｖｍａｔ２インヒビター
JP2024122223A Pending JP2024153782A (ja) 2014-05-06 2024-07-29 多動性運動障害を処置するためのｖｍａｔ２インヒビター

Country Status (24)

Country Link
US (3) US20170071932A1 (OSRAM)
EP (3) EP3936130B1 (OSRAM)
JP (4) JP6635945B2 (OSRAM)
KR (5) KR20200133003A (OSRAM)
CN (3) CN106456629A (OSRAM)
AU (1) AU2015256012B2 (OSRAM)
CA (1) CA2947736C (OSRAM)
CY (1) CY1125058T1 (OSRAM)
DK (2) DK3139925T3 (OSRAM)
ES (2) ES2976207T3 (OSRAM)
FI (1) FI3936130T3 (OSRAM)
HR (2) HRP20240459T1 (OSRAM)
HU (2) HUE066361T2 (OSRAM)
IL (1) IL248745B (OSRAM)
LT (2) LT3936130T (OSRAM)
MX (1) MX387625B (OSRAM)
NZ (1) NZ725826A (OSRAM)
PL (2) PL3139925T3 (OSRAM)
PT (2) PT3139925T (OSRAM)
RS (2) RS65359B1 (OSRAM)
RU (1) RU2753740C2 (OSRAM)
SI (2) SI3936130T1 (OSRAM)
SM (2) SMT202400199T1 (OSRAM)
WO (1) WO2015171802A1 (OSRAM)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2972600T3 (es) 2015-10-30 2024-06-13 Neurocrine Biosciences Inc Sales de diclorhidrato de valbenazina y polimorfos de las mismas
DK3394057T3 (da) 2015-12-23 2022-04-11 Neurocrine Biosciences Inc Syntetisk fremgangsmåde til fremstilling af (S)-(2R,3R,11BR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11B-hexahydro-1H-pyrido[2,1,-A]isoquinolin-2-yl 2-amino-3-methylbutanoat-di(4-methylbenzensulfonat)
ES2811048T3 (es) * 2016-06-29 2021-03-10 Crystal Pharmaceutical Suzhou Co Ltd Formas cristalinas de NBI-98854, método de preparación para las mismas y uso de las mismas
TW202515564A (zh) * 2016-12-02 2025-04-16 美商紐羅克里生物科學有限公司 戊苯那嗪（valbenazine）於治療精神分裂症或情感性精神分裂症之用途
WO2018130345A1 (en) 2017-01-10 2018-07-19 Sandoz Ag Crystalline valbenazine free base
JP7199359B2 (ja) 2017-01-27 2023-01-05 ニューロクライン バイオサイエンシーズ，インコーポレイテッド 特定のｖｍａｔ２インヒビターを投与するための方法
US10954235B2 (en) 2017-02-27 2021-03-23 Sandoz Ag Crystalline forms of valbenazine salts
WO2018164996A1 (en) * 2017-03-06 2018-09-13 Neurocrine Biosciences, Inc. Dosing regimen for valbenazine
GB201705305D0 (en) * 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
US20190111035A1 (en) * 2017-04-01 2019-04-18 Adeptio Pharmaceuticals Limited Pharmaceutical compositions
GB201705306D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705302D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
RU2771164C2 (ru) * 2017-04-01 2022-04-27 Адептио Фармасьютикалз Лимитед (+)-альфа-дигидротетрабеназин для использования при лечении двигательного расстройства
WO2018178243A2 (en) * 2017-04-01 2018-10-04 Adeptio Pharmaceuticals Limited Pharmaceutical compositions
GB201705304D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705303D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
WO2018200605A1 (en) * 2017-04-26 2018-11-01 Neurocrine Biosciences, Inc. Use of valbenazine for treating levodopa-induced dyskinesia
BR112020005373A2 (pt) 2017-09-21 2020-09-24 Neurocrine Biosciences Inc. formulação de valbenazina em alta dosagem e composições, métodos e kits relacionados com valbenazina
KR20250070134A (ko) 2017-10-10 2025-05-20 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 vmat2 억제제의 투여 방법
SG11202003194YA (en) * 2017-10-10 2020-05-28 Neurocrine Biosciences Inc Methods for the administration of certain vmat2 inhibitors
EP3706748A4 (en) * 2017-11-08 2021-08-11 Foresee Pharmaceuticals Co., Ltd. ESTER OF DIHYDROTETRABENAZINE
US11339158B2 (en) 2017-12-26 2022-05-24 Crystal Pharmaceutical (Suzhou) Co., Ltd. Crystalline form of valbenazine ditosylate, processes for preparation thereof and use thereof
TWI832854B (zh) * 2018-04-25 2024-02-21 美商神經治療股份有限公司 丁苯那嗪經皮輸送裝置
GB201808464D0 (en) 2018-05-23 2018-07-11 Adeptio Pharmaceuticals Ltd Pharmaceutical compounds for use in treating huntington's disease
TW202011963A (zh) 2018-06-14 2020-04-01 美商紐羅克里生物科學有限公司 Vmat2抑制劑化合物、組合物及其相關方法
MA53239A (fr) 2018-08-15 2022-05-04 Neurocrine Biosciences Inc Procédés d'administration de certains inhibiteurs de vmat2
EP3860599B1 (en) 2018-10-04 2024-05-15 Adeptio Pharmaceuticals Limited (+)-alpha-dihydrotetrabenazine dosage regimen for treating movement disorders
JP2022531696A (ja) * 2019-05-09 2022-07-08 ニューロクライン バイオサイエンシーズ，インコーポレイテッド 特定のｖｍａｔ２阻害剤を投与するための方法
US10940141B1 (en) 2019-08-23 2021-03-09 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007317242B2 (en) * 2006-11-08 2013-08-01 Neurocrine Biosciences, Inc. Substituted 3-isobutyl-9, 10-dimethoxy-1,3,4,6,7,11B-hexahydro-2H-pyrido[2,1-a] isoquinolin-2-ol compounds and methods relating thereto
WO2008060451A2 (en) * 2006-11-09 2008-05-22 New York University Graded glass/zirconia/glass structures for damage resistant ceramic dental and orthopedic prostheses
GB2462611A (en) 2008-08-12 2010-02-17 Cambridge Lab Pharmaceutical composition comprising tetrabenazine
US20110053866A1 (en) * 2008-08-12 2011-03-03 Biovail Laboratories International (Barbados) S.R.L. Pharmaceutical compositions
US8524733B2 (en) 2008-09-18 2013-09-03 Auspex Pharmaceuticals Benzoquinoline inhibitors of vesicular monoamine transporter 2
JP2013501810A (ja) * 2009-08-12 2013-01-17 ヴァリーント インターナショナル（バルバドス）エスアールエル 医薬組成物
WO2011153157A2 (en) * 2010-06-01 2011-12-08 Auspex Pharmaceutical, Inc. Benzoquinolone inhibitors of vmat2
IN2015DN01662A (OSRAM) * 2012-09-18 2015-07-03 Auspex Pharmaceuticals Inc
CN113368110A (zh) * 2014-02-07 2021-09-10 纽罗克里生物科学有限公司 包含抗精神病药物和vmat2抑制剂的药物组合物及其用途

Similar Documents

Publication Publication Date Title
JP2017514850A5 (OSRAM)
JP6635945B2 (ja) 多動性運動障害を処置するためのｖｍａｔ２インヒビター
PH12020550238A1 (en) Methods for the administration of certain vmat2 inhibitors
JP7221922B2 (ja) 組み合せ抗細菌組成物および短期抗細菌レジメン
JP2017525718A5 (OSRAM)
RU2013113222A (ru) Способы лечения или профилактики тромбообразования или эмболии
BR112014003061A2 (pt) composição farmacêutica com sabor mascarado
JP2016540738A5 (OSRAM)
WO2011113802A3 (en) Imidazopyridine and purine compounds, compositions and methods of use
RU2014102362A (ru) Антитромботические соединения
MX2021011563A (es) Derivados de 2,3-dihidro-isoindol-1-ona, como inhibidores de la btk quinasa y composiciones farmaceuticas que los incluyen.
WO2013022783A3 (en) Progesterone containing oral dosage forms and related methods
JP2015038155A5 (OSRAM)
WO2016210003A3 (en) 17-hydroxyprogesterone ester-containing oral compositions and related methods
WO2011118976A3 (en) Pharmaceutical composition for the prevention or the treatment of non-alcoholic fatty liver disease and the method for prevention or treatment of non-alcoholic fatty liver disease using the same
JP2013508289A5 (OSRAM)
JP2012502047A5 (OSRAM)
JP2015509539A5 (OSRAM)
TN2022000092A1 (en) Oral complement factor d inhibitors
MX418886B (es) Derivado de pirimidina que inhibe el crecimiento de celulas cancerosas y uso medicinal del mismo
FI3706724T3 (fi) Suun kautta otettavia rifamysiini sv -koostumuksia
PH12022550794A1 (en) Oral complement factor d inhibitors
JP2015504094A5 (OSRAM)
RU2019109695A (ru) Лекарственная форма для пролонгированного ослабления симптомов
JP2016515550A5 (OSRAM)